 Thomas Beresford
Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 18 | 2023 | 717 | 3.830 |
Why?
| | Disulfiram | 6 | 2007 | 13 | 1.490 |
Why?
| | Alcohol Deterrents | 6 | 2007 | 17 | 1.490 |
Why?
| | Immunosuppressive Agents | 4 | 2019 | 666 | 1.440 |
Why?
| | Cyclosporine | 3 | 2018 | 169 | 1.210 |
Why?
| | Calcineurin | 3 | 2019 | 84 | 1.170 |
Why?
| | Alcohol Drinking | 5 | 2018 | 650 | 1.070 |
Why?
| | Cocaine-Related Disorders | 4 | 2017 | 107 | 1.060 |
Why?
| | Defense Mechanisms | 3 | 2014 | 24 | 0.990 |
Why?
| | Alcohol-Related Disorders | 4 | 2014 | 110 | 0.930 |
Why?
| | Antipsychotic Agents | 3 | 2017 | 183 | 0.860 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2023 | 160 | 0.830 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2018 | 85 | 0.830 |
Why?
| | Aripiprazole | 3 | 2017 | 17 | 0.810 |
Why?
| | Cost of Illness | 2 | 2014 | 257 | 0.790 |
Why?
| | Liver Transplantation | 4 | 2018 | 830 | 0.700 |
Why?
| | Schizophrenia | 2 | 2017 | 418 | 0.630 |
Why?
| | Nervous System Diseases | 2 | 2019 | 253 | 0.620 |
Why?
| | Perphenazine | 1 | 2017 | 1 | 0.610 |
Why?
| | Dopamine Agents | 1 | 2017 | 13 | 0.600 |
Why?
| | Craving | 1 | 2017 | 31 | 0.590 |
Why?
| | Brain Injuries, Traumatic | 1 | 2022 | 301 | 0.570 |
Why?
| | Ego | 2 | 2006 | 11 | 0.530 |
Why?
| | Jurisprudence | 2 | 2005 | 13 | 0.490 |
Why?
| | Cannabinoids | 1 | 2015 | 116 | 0.460 |
Why?
| | Ethanol | 4 | 2023 | 549 | 0.450 |
Why?
| | Hepatitis C | 3 | 2007 | 229 | 0.450 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2005 | 43 | 0.450 |
Why?
| | Psychotherapy | 1 | 2014 | 149 | 0.410 |
Why?
| | Brain | 2 | 2015 | 2373 | 0.410 |
Why?
| | Models, Psychological | 1 | 2014 | 299 | 0.410 |
Why?
| | Hippocampus | 2 | 2006 | 709 | 0.400 |
Why?
| | Patient Compliance | 3 | 2007 | 524 | 0.390 |
Why?
| | Tacrolimus | 1 | 2012 | 143 | 0.370 |
Why?
| | Sirolimus | 1 | 2012 | 192 | 0.370 |
Why?
| | Neurology | 1 | 2010 | 85 | 0.340 |
Why?
| | Cannabis | 1 | 2015 | 385 | 0.330 |
Why?
| | Inflammation | 1 | 2019 | 2500 | 0.320 |
Why?
| | Humans | 39 | 2023 | 115739 | 0.320 |
Why?
| | Double-Blind Method | 4 | 2022 | 1660 | 0.290 |
Why?
| | Stearates | 1 | 2007 | 1 | 0.290 |
Why?
| | Palmitic Acids | 1 | 2007 | 9 | 0.290 |
Why?
| | Oleic Acids | 1 | 2007 | 10 | 0.290 |
Why?
| | Behavior, Addictive | 1 | 2007 | 78 | 0.280 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2006 | 9 | 0.280 |
Why?
| | Bipolar Disorder | 5 | 2006 | 208 | 0.270 |
Why?
| | Sick Role | 1 | 2006 | 19 | 0.270 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 465 | 0.270 |
Why?
| | Serum Albumin | 1 | 2007 | 135 | 0.270 |
Why?
| | Mental Disorders | 1 | 2014 | 902 | 0.270 |
Why?
| | Valproic Acid | 2 | 2022 | 43 | 0.260 |
Why?
| | Depressive Disorder, Major | 2 | 2020 | 304 | 0.260 |
Why?
| | Food Handling | 2 | 2016 | 48 | 0.260 |
Why?
| | Anxiety Disorders | 2 | 2005 | 310 | 0.250 |
Why?
| | Male | 25 | 2018 | 56048 | 0.250 |
Why?
| | Middle Aged | 19 | 2017 | 27069 | 0.240 |
Why?
| | Hydrocortisone | 1 | 2006 | 273 | 0.240 |
Why?
| | Administration, Sublingual | 1 | 2004 | 13 | 0.230 |
Why?
| | Mood Disorders | 1 | 2005 | 117 | 0.230 |
Why?
| | Quinolones | 1 | 2005 | 97 | 0.230 |
Why?
| | Teaching | 1 | 2005 | 224 | 0.220 |
Why?
| | Anticonvulsants | 1 | 2005 | 181 | 0.220 |
Why?
| | Cocaine | 2 | 2009 | 153 | 0.220 |
Why?
| | Diagnosis, Dual (Psychiatry) | 2 | 2017 | 35 | 0.210 |
Why?
| | Piperazines | 1 | 2005 | 314 | 0.210 |
Why?
| | Psychiatry | 1 | 2005 | 155 | 0.210 |
Why?
| | Signal Transduction | 1 | 2015 | 4541 | 0.210 |
Why?
| | Postoperative Care | 1 | 2004 | 222 | 0.210 |
Why?
| | Adult | 18 | 2017 | 30788 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 1870 | 0.200 |
Why?
| | Learning | 1 | 2005 | 358 | 0.200 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 551 | 0.190 |
Why?
| | Irritable Mood | 1 | 2022 | 48 | 0.190 |
Why?
| | Prognosis | 3 | 2018 | 3343 | 0.190 |
Why?
| | Depressive Disorder, Treatment-Resistant | 1 | 2020 | 4 | 0.190 |
Why?
| | Animals | 8 | 2019 | 32104 | 0.180 |
Why?
| | Brain Injuries | 1 | 2005 | 451 | 0.180 |
Why?
| | Lactobacillus helveticus | 2 | 2009 | 2 | 0.170 |
Why?
| | Antidepressive Agents | 2 | 2020 | 195 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2006 | 485 | 0.170 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 4773 | 0.160 |
Why?
| | DNA Transposable Elements | 2 | 2009 | 100 | 0.160 |
Why?
| | Female | 20 | 2017 | 60016 | 0.160 |
Why?
| | Cheese | 2 | 2016 | 5 | 0.160 |
Why?
| | Alcohol Abstinence | 1 | 2018 | 10 | 0.150 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 72 | 0.150 |
Why?
| | Binge-Eating Disorder | 1 | 2018 | 16 | 0.150 |
Why?
| | Injections, Intraperitoneal | 1 | 2018 | 104 | 0.150 |
Why?
| | Depression | 1 | 2006 | 1147 | 0.150 |
Why?
| | Neuroimmunomodulation | 1 | 2018 | 71 | 0.150 |
Why?
| | Medical History Taking | 1 | 2018 | 114 | 0.150 |
Why?
| | Brain Chemistry | 1 | 2018 | 116 | 0.150 |
Why?
| | Bupropion | 1 | 2017 | 39 | 0.150 |
Why?
| | Drug Substitution | 1 | 2017 | 46 | 0.140 |
Why?
| | Comorbidity | 4 | 2017 | 1473 | 0.140 |
Why?
| | Volatile Organic Compounds | 1 | 2016 | 45 | 0.130 |
Why?
| | Internship and Residency | 1 | 2005 | 951 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2018 | 248 | 0.130 |
Why?
| | Community Mental Health Services | 2 | 2006 | 84 | 0.130 |
Why?
| | Severity of Illness Index | 1 | 2023 | 2586 | 0.130 |
Why?
| | Probability | 2 | 2006 | 294 | 0.130 |
Why?
| | Patient Selection | 1 | 2018 | 654 | 0.120 |
Why?
| | Cooperative Behavior | 2 | 2006 | 390 | 0.110 |
Why?
| | Health Facilities | 1 | 2014 | 71 | 0.110 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2006 | 231 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2022 | 9162 | 0.110 |
Why?
| | Veterans | 4 | 2017 | 1234 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2006 | 4442 | 0.100 |
Why?
| | United States | 7 | 2017 | 12304 | 0.100 |
Why?
| | Neoplasms | 1 | 2006 | 2118 | 0.100 |
Why?
| | Mice | 3 | 2018 | 15052 | 0.100 |
Why?
| | Hospitals, Veterans | 4 | 2006 | 245 | 0.100 |
Why?
| | Sucrose | 1 | 2012 | 91 | 0.100 |
Why?
| | Patient Care Team | 2 | 2006 | 521 | 0.100 |
Why?
| | Self Administration | 1 | 2012 | 124 | 0.100 |
Why?
| | Amphetamine-Related Disorders | 1 | 2011 | 29 | 0.100 |
Why?
| | Benzhydryl Compounds | 1 | 2011 | 60 | 0.090 |
Why?
| | Methamphetamine | 1 | 2011 | 52 | 0.090 |
Why?
| | Drug Interactions | 1 | 2012 | 347 | 0.090 |
Why?
| | Pilot Projects | 2 | 2005 | 1384 | 0.090 |
Why?
| | Ligands | 1 | 2012 | 569 | 0.090 |
Why?
| | Central Nervous System Stimulants | 1 | 2011 | 140 | 0.090 |
Why?
| | DNA Fingerprinting | 1 | 2009 | 27 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 41 | 0.080 |
Why?
| | Baclofen | 1 | 2009 | 10 | 0.080 |
Why?
| | Genome, Bacterial | 1 | 2009 | 106 | 0.080 |
Why?
| | Intensive Care Units | 1 | 2013 | 622 | 0.080 |
Why?
| | Calcium | 1 | 2014 | 1103 | 0.080 |
Why?
| | Psychology | 2 | 2006 | 83 | 0.080 |
Why?
| | DNA, Bacterial | 1 | 2009 | 309 | 0.080 |
Why?
| | Liver | 2 | 2007 | 1690 | 0.080 |
Why?
| | Temperance | 1 | 2007 | 14 | 0.080 |
Why?
| | Behavior Therapy | 2 | 2009 | 225 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 342 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2013 | 683 | 0.070 |
Why?
| | Liver Failure | 1 | 2007 | 84 | 0.070 |
Why?
| | Liver Function Tests | 1 | 2007 | 105 | 0.070 |
Why?
| | Disease Management | 1 | 2010 | 563 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2006 | 125 | 0.060 |
Why?
| | Skull | 1 | 2006 | 117 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 440 | 0.060 |
Why?
| | Esters | 1 | 2006 | 61 | 0.060 |
Why?
| | Carbamazepine | 1 | 2005 | 18 | 0.060 |
Why?
| | Saliva | 1 | 2006 | 189 | 0.060 |
Why?
| | Education | 1 | 2005 | 99 | 0.060 |
Why?
| | Genomics | 1 | 2009 | 646 | 0.060 |
Why?
| | History, 20th Century | 1 | 2006 | 273 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 778 | 0.060 |
Why?
| | Aspartate Aminotransferases | 1 | 2004 | 87 | 0.060 |
Why?
| | Regression Analysis | 1 | 2006 | 959 | 0.060 |
Why?
| | Social Support | 1 | 2007 | 539 | 0.060 |
Why?
| | Alanine Transaminase | 1 | 2004 | 141 | 0.060 |
Why?
| | Practice Guidelines as Topic | 3 | 2006 | 1405 | 0.060 |
Why?
| | Aged | 3 | 2014 | 19294 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 501 | 0.050 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 230 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 391 | 0.050 |
Why?
| | Fatty Acids | 1 | 2006 | 386 | 0.050 |
Why?
| | Minority Groups | 1 | 2005 | 230 | 0.050 |
Why?
| | Prospective Studies | 2 | 2005 | 6276 | 0.050 |
Why?
| | Survival Analysis | 1 | 2006 | 1219 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2006 | 1178 | 0.050 |
Why?
| | Quality of Life | 2 | 2020 | 2388 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1127 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2003 | 184 | 0.050 |
Why?
| | United States Department of Veterans Affairs | 1 | 2005 | 557 | 0.050 |
Why?
| | Motivation | 1 | 2005 | 498 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2013 | 12633 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2005 | 497 | 0.050 |
Why?
| | Health Status | 1 | 2005 | 728 | 0.040 |
Why?
| | Risk Factors | 3 | 2013 | 8702 | 0.040 |
Why?
| | Outpatients | 1 | 2003 | 330 | 0.040 |
Why?
| | Curriculum | 1 | 2005 | 855 | 0.040 |
Why?
| | Time Factors | 2 | 2006 | 6171 | 0.040 |
Why?
| | Reducing Agents | 1 | 2016 | 3 | 0.040 |
Why?
| | Substance-Related Disorders | 1 | 2005 | 951 | 0.030 |
Why?
| | Remission Induction | 1 | 2017 | 240 | 0.030 |
Why?
| | Drug Resistance | 1 | 2017 | 162 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 317 | 0.030 |
Why?
| | Case Management | 2 | 2006 | 62 | 0.030 |
Why?
| | Oxidants | 1 | 2016 | 112 | 0.030 |
Why?
| | Sodium Chloride | 1 | 2016 | 136 | 0.030 |
Why?
| | Health Services Accessibility | 3 | 2006 | 773 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3122 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 515 | 0.030 |
Why?
| | Health Plan Implementation | 2 | 2006 | 133 | 0.030 |
Why?
| | Patient Readmission | 2 | 2013 | 609 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 962 | 0.030 |
Why?
| | Taste | 1 | 2016 | 208 | 0.030 |
Why?
| | Rheology | 1 | 2014 | 88 | 0.030 |
Why?
| | Solubility | 1 | 2014 | 226 | 0.030 |
Why?
| | Continuity of Patient Care | 2 | 2006 | 255 | 0.030 |
Why?
| | Self Care | 2 | 2006 | 354 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2006 | 548 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 924 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2006 | 686 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2011 | 65 | 0.020 |
Why?
| | Psychotherapy, Group | 1 | 2011 | 61 | 0.020 |
Why?
| | Chronic Disease | 2 | 2006 | 1598 | 0.020 |
Why?
| | Cohort Studies | 2 | 2013 | 4947 | 0.020 |
Why?
| | DNA Restriction-Modification Enzymes | 1 | 2009 | 1 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 404 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2009 | 28 | 0.020 |
Why?
| | GABA Agonists | 1 | 2009 | 17 | 0.020 |
Why?
| | Food Microbiology | 1 | 2009 | 57 | 0.020 |
Why?
| | Limbic System | 1 | 2009 | 43 | 0.020 |
Why?
| | Multigene Family | 1 | 2009 | 193 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 197 | 0.020 |
Why?
| | Employment | 1 | 2009 | 139 | 0.020 |
Why?
| | Safety | 1 | 2009 | 298 | 0.020 |
Why?
| | Educational Status | 1 | 2009 | 414 | 0.020 |
Why?
| | Medication Adherence | 1 | 2011 | 538 | 0.020 |
Why?
| | Counseling | 1 | 2009 | 347 | 0.020 |
Why?
| | Calibration | 1 | 2006 | 129 | 0.020 |
Why?
| | Pensions | 1 | 2005 | 4 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2005 | 34 | 0.020 |
Why?
| | Public Sector | 1 | 2005 | 18 | 0.020 |
Why?
| | Personality Assessment | 1 | 2005 | 79 | 0.020 |
Why?
| | Combat Disorders | 1 | 2005 | 33 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2005 | 91 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2005 | 4448 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2005 | 299 | 0.010 |
Why?
| | California | 1 | 2005 | 367 | 0.010 |
Why?
| | Disability Evaluation | 1 | 2005 | 271 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2824 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1730 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2005 | 479 | 0.010 |
Why?
| | Indians, North American | 1 | 2005 | 584 | 0.010 |
Why?
| | Age Factors | 1 | 2005 | 2911 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 1765 | 0.010 |
Why?
|
|
Beresford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|